Braidwell LP Cuts Stake in Kiniksa Pharmaceuticals International, plc $KNSA

Braidwell LP lessened its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 32.5% in the 2nd quarter, Holdings Channel reports. The firm owned 183,822 shares of the company’s stock after selling 88,700 shares during the period. Braidwell LP’s holdings in Kiniksa Pharmaceuticals International were worth $11,755,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Qube Research & Technologies Ltd boosted its holdings in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after buying an additional 653,236 shares during the last quarter. Rubric Capital Management LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after acquiring an additional 526,567 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 213.2% in the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock valued at $18,192,000 after acquiring an additional 447,536 shares in the last quarter. Finally, Spruce Street Capital LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the fourth quarter worth approximately $17,943,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of the business’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the transaction, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $79.89 on Thursday. The stock has a market cap of $6.23 billion, a P/E ratio of 82.36 and a beta of 0.09. The stock’s 50 day simple moving average is $71.13 and its 200-day simple moving average is $56.97. Kiniksa Pharmaceuticals International, plc has a 1-year low of $34.00 and a 1-year high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%.The business had revenue of $243.60 million during the quarter, compared to analyst estimates of $226.49 million. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on the company. Canaccord Genuity Group boosted their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. The Goldman Sachs Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has an average rating of “Moderate Buy” and an average target price of $87.38.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.